Germany· DE-A57-505a7fd32e2a48c2
Enzalutamid Hexal
A enzalutamide product containing enzalutamide, registered in Germany by Adalvo Limited. The same ATC class is registered in 16 of our 19 countries.
Checked against EMA Article 57 (European Union) on
Informational only — not a medical device.
Where it is registered
Enzalutamide is registered in 16 of 19 countries.
Countries holding a registration under ATC L02BB04 (enzalutamide), each read from that country’s own register.
- This record: Germany, from EMA Article 57 (European Union)
- 9 of them publish a price we can compare per daily dose
Enzalutamide · ATC L02BB04
16 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of enzalutamide costs, country by country.
Normalised to the WHO defined daily dose (0.16 g), the median price runs from $0.46 in France to $135.12 in Switzerland — a ×295 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Enzalutamide · price per daily dose (0.16 g)
USD · FX 28 Sept 2026
- CH Switzerland$135.12
- FR France$0.46
The record
At a glance
EMA Article 57 (European Union)- Active substance
- Enzalutamide
- Manufacturer
- Adalvo Limited
- Country
- Germany (DE)
- ATC code
- L02BB04
- ATC class
- Enzalutamide
- Defined daily dose
- 0.16 g, O
- Reimbursed
- Not published by this register
- Source register
- EMA Article 57 (European Union)
- Last checked
- September 30, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
706 interactions on record for enzalutamide.
Graded by severity as the source publishes them — 241 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Enzalutamide · interactions on record
706 records
- 241 severe
- 448 moderate
- 17 minor
Most severe, free to view
- PapaverineA03AD01severe
- CisaprideA03FA02severe
- DolasetronA04AA04severe
- RolapitantA04AD14severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under L02BB04
Enzalutamide, as other registers publish it.
- GermanyEnzalutamid AccordAccord Healthcare B.V.
- GermanyEnzalutamid AlAliud Pharma Gmbh
- GermanyEnzalutamid HexalHexal Ag
- GermanyEnzalutamid RatiopharmRatiopharm Gmbh
- PolandEnzalutamid SandozSandoz Polska Sp. z o.o.
- PolandEnzalutamid SandozSandoz Polska Sp. z o.o.
- CzechiaENZALUTAMID SANDOZSandoz s.r.o., Praha
- CzechiaENZALUTAMID SANDOZSandoz s.r.o., Praha
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of EMA Article 57 (European Union). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/31093275-39c3-4076-8a10-cb11d27f4d52 GET /v1/drugs/31093275-39c3-4076-8a10-cb11d27f4d52?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"pzn": null,
"route": "Oral Use",
"source": "ema_art57_de",
"ma_number": null,
"substance": "Enzalutamide",
"atc_from_source": null,
"authorisation_country": "Germany"
}See everything about enzalutamide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.